Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for Lipocine (LPCN) over the last 10 years, with Q3 2025 value amounting to $5.9 million.

  • Lipocine's Change in Acquisitions & Divestments fell 1194.03% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.1 million, marking a year-over-year decrease of 3216.22%. This contributed to the annual value of $35.4 million for FY2024, which is 166.67% down from last year.
  • According to the latest figures from Q3 2025, Lipocine's Change in Acquisitions & Divestments is $5.9 million, which was down 1194.03% from $4.5 million recorded in Q2 2025.
  • In the past 5 years, Lipocine's Change in Acquisitions & Divestments ranged from a high of $25.2 million in Q1 2022 and a low of $450000.0 during Q1 2021
  • In the last 5 years, Lipocine's Change in Acquisitions & Divestments had a median value of $6.7 million in 2024 and averaged $8.3 million.
  • As far as peak fluctuations go, Lipocine's Change in Acquisitions & Divestments tumbled by 8965.52% in 2021, and later skyrocketed by 550632.76% in 2022.
  • Over the past 5 years, Lipocine's Change in Acquisitions & Divestments (Quarter) stood at $1.4 million in 2021, then skyrocketed by 914.29% to $14.2 million in 2022, then fell by 14.79% to $12.1 million in 2023, then dropped by 13.22% to $10.5 million in 2024, then crashed by 43.81% to $5.9 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $5.9 million for Q3 2025, versus $4.5 million for Q2 2025 and $4.2 million for Q1 2025.